{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.30","upperLimit":"12.02","value":"11.01"},{"groupId":"OG001","lowerLimit":"6.60","upperLimit":"8.84","value":"7.59"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"226"}],"units":"Participants"}],"description":"PFS 2 was defined as the time from date of randomization until second disease progression or death whichever occurred first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants randomized to single-agent MIRV at 6 mg/kg AIBW administered IV on Day 1 of Q3W.","id":"OG000","title":"Mirvetuximab Soravtansine"},{"description":"Participants randomized to IC chemotherapeutic agent calculated using BSA. Paclitaxel administered at 80 mg/m\\^2 as a 1-hour IV infusion on Days 1, 8, 15, and 22 of a 4-week cycle; or topotecan administered at 4 mg/m\\^2 over 30 minutes on Days 1, 8, and 15 of a 4-week cycle. Alternatively, topotecan could have been administered at 1.25 mg/m\\^2 over 30 minutes on Days 1 to 5 of a 3-week cycle; or pegylated liposomal doxorubicin administered at 40 mg/m\\^2 as a 1 mg/minute IV infusion on Day 1 of a 4-week cycle. After Cycle 1, if tolerated, pegylated liposomal doxorubicin could have been administered as a 1-hour infusion.","id":"OG001","title":"Investigator's Choice (IC) Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"The ITT population included all participants randomized to the study, regardless of whether or not participants received study treatment (MIRV or IC Chemo).","reportingStatus":"POSTED","timeFrame":"Up to approximately 44 months","title":"Time to Second Progression-Free Survival (PFS 2)","type":"SECONDARY","unitOfMeasure":"months"}